MARKET

LXRX

LXRX

Lexicon Pharmaceuticals Inc
NASDAQ
0.3720
+0.0150
+4.20%
Opening 10:39 03/14 EDT
OPEN
0.3590
PREV CLOSE
0.3570
HIGH
0.3720
LOW
0.3552
VOLUME
1.31M
TURNOVER
--
52 WEEK HIGH
2.829
52 WEEK LOW
0.2836
MARKET CAP
134.48M
P/E (TTM)
-0.5941
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LXRX last week (0303-0307)?
Weekly Report · 4d ago
Lexicon Pharmaceuticals Faces Supply Chain Risks Amidst Changing Trade Policies
TipRanks · 5d ago
Vistra, Ardelyx, Zscaler, Lexicon, Arista: Trending by Analysts
TipRanks · 6d ago
Lexicon Pharmaceuticals’ Mixed Earnings Call: Achievements and Challenges
TipRanks · 6d ago
Lexicon Pharmaceuticals, Inc. (LXRX) Annual Report (Form 10-K) for the Fiscal Year Ended December 31, 2024
Press release · 6d ago
Lexicon Pharmaceuticals GAAP EPS of -$0.09 beats by $0.02, revenue of $26.6M beats by $24.6M
Seeking Alpha · 6d ago
Lexicon Pharma Is Maintained at Overweight by Piper Sandler
Dow Jones · 6d ago
Lexicon Pharma Price Target Cut to $6.00/Share From $10.00 by Piper Sandler
Dow Jones · 6d ago
More
About LXRX
More
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.
Recently
Symbol
Price
%Change

Webull offers Lexicon Pharmaceuticals Inc stock information, including NASDAQ: LXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LXRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LXRX stock methods without spending real money on the virtual paper trading platform.